Holders — by stockHoldings — by fund
Pivotal bioVenture Partners Investment Advisor LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001844645
$307.8M
disclosed book value
13
positions
26.9%
largest position share
Positions, as of 2026-06-30
top 13 of 13 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PCVXVAXCYTE INC | 1.4M | $82.9M | 26.9% |
| 2 | ARQTARCUTIS BIOTHERAPEUTICS INC | 1.3M | $33.2M | 10.8% |
| 3 | TRVITREVI THERAPEUTICS INC | 1.7M | $32.5M | 10.6% |
| 4 | AVLNAVALYN PHARMACEUTICALS INC | 966,792 | $31.8M | 10.3% |
| 5 | EVMNEVOMMUNE INC | 1.9M | $25.6M | 8.3% |
| 6 | MPLTMAPLIGHT THERAPEUTICS INC | 611,446 | $21.9M | 7.1% |
| 7 | OCULIS HOLDING AG | 1.5M | $20.9M | 6.8% |
| 8 | BIOABIOAGE LABS INC | 653,374 | $16.0M | 5.2% |
| 9 | IMNMIMMUNOME INC | 732,512 | $15.5M | 5% |
| 10 | ZBIOZENAS BIOPHARMA INC | 490,766 | $12.5M | 4% |
| 11 | AVTXAVALO THERAPEUTICS INC | 434,033 | $8.0M | 2.6% |
| 12 | RLYBRALLYBIO CORP | 300,579 | $4.8M | 1.6% |
| 13 | RXRXRECURSION PHARMACEUTICALS IN | 595,518 | $2.2M | 0.7% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.